UY25668A1 - Polimorfo de monohidrato de zopolrestat - Google Patents
Polimorfo de monohidrato de zopolrestatInfo
- Publication number
- UY25668A1 UY25668A1 UY25668A UY25668A UY25668A1 UY 25668 A1 UY25668 A1 UY 25668A1 UY 25668 A UY25668 A UY 25668A UY 25668 A UY25668 A UY 25668A UY 25668 A1 UY25668 A1 UY 25668A1
- Authority
- UY
- Uruguay
- Prior art keywords
- zopolrestat
- polymorph
- compositions
- monohydrate
- uric acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a composiciones de monohidrato de zopolrestat y a procedimientos de uso del mismo y de las composiciones del mismo para tratar complicaciones diabéticas, reducir los niveles de lípidos en sangre o el nivel de ácido úrico en sangre. El zolpolrestat es conocido como ácido 3,4,-dihidro-4-oxo-3-((5-trifluorometil)-2-benzotiazolil)metil-1-ftalilbencilacético Esta invención proporciona un procedimiento para prepara zopolrestat anhidro que comprende secar un polimorfo de monohidrato de zopolrestar, calentando el polimorfo en agua antes de secar Además comprende tratar la cardiomiopatía diabética , un procedimiento para tratar la cardiopatía, para reducir los niveles de ácido úrico en sangre, para reducir los niveles lipídicos en sangre, para prevenir el dolor por angina, para prevenir la lesinn cardíaca derivada deisquemia de miocardio
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9747498P | 1998-08-21 | 1998-08-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY25668A1 true UY25668A1 (es) | 2001-08-27 |
Family
ID=22263562
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY25668A UY25668A1 (es) | 1998-08-21 | 1999-08-19 | Polimorfo de monohidrato de zopolrestat |
Country Status (31)
Country | Link |
---|---|
US (1) | US6159976A (es) |
EP (1) | EP0982306A3 (es) |
JP (1) | JP2000072769A (es) |
KR (1) | KR20000017411A (es) |
CN (1) | CN1245804A (es) |
AP (1) | AP9901662A0 (es) |
AU (1) | AU4453299A (es) |
BG (1) | BG103674A (es) |
BR (1) | BR9903873A (es) |
CA (1) | CA2280590A1 (es) |
EA (1) | EA199900675A3 (es) |
EE (1) | EE9900385A (es) |
GT (1) | GT199900137A (es) |
HR (1) | HRP990259A2 (es) |
HU (1) | HUP9902783A3 (es) |
ID (1) | ID23307A (es) |
IL (1) | IL131419A0 (es) |
IS (1) | IS5155A (es) |
MA (1) | MA26678A1 (es) |
NO (1) | NO994027L (es) |
NZ (1) | NZ337363A (es) |
OA (1) | OA11150A (es) |
PA (1) | PA8480601A1 (es) |
PE (1) | PE20000993A1 (es) |
PL (1) | PL335016A1 (es) |
SG (1) | SG83147A1 (es) |
TN (1) | TNSN99159A1 (es) |
TR (1) | TR199901996A2 (es) |
UY (1) | UY25668A1 (es) |
YU (1) | YU39899A (es) |
ZA (1) | ZA995297B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5934206B2 (ja) | 2010-07-16 | 2016-06-15 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | アルドース還元酵素阻害剤および同使用方法 |
US8916563B2 (en) | 2010-07-16 | 2014-12-23 | The Trustees Of Columbia University In The City Of New York | Aldose reductase inhibitors and uses thereof |
US20140228319A1 (en) * | 2013-02-13 | 2014-08-14 | Banavara L. Mylari | Water soluble salts of aldose reductase inhibitors for treatment of diabetic complications |
ES2836500T3 (es) | 2016-06-21 | 2021-06-25 | Univ Columbia | Inhibidores de aldosa reductasa y métodos de uso de los mismos |
US11590131B2 (en) | 2017-07-28 | 2023-02-28 | Applied Therapeutics, Inc. | Compositions and methods for treating galactosemia |
SG11202110590PA (en) | 2019-04-01 | 2021-10-28 | Applied Therapeutics Inc | Inhibitors of aldose reductase |
WO2021202523A1 (en) | 2020-03-31 | 2021-10-07 | Applied Therapeutics, Inc. | Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy |
CN115996725A (zh) | 2020-05-01 | 2023-04-21 | 应用治疗公司 | 用于治疗山梨糖醇脱氢酶缺乏症的醛糖还原酶抑制剂 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4939140A (en) * | 1985-11-07 | 1990-07-03 | Pfizer Inc. | Heterocyclic oxophthalazinyl acetic acids |
US4748280A (en) * | 1985-11-07 | 1988-05-31 | Pfizer Inc. | Certain chlorination process for preparing 2-chloro-1,1,1-(C1 -C6) |
JPH0676391B2 (ja) * | 1987-06-09 | 1994-09-28 | フアイザー・インコーポレイテツド | ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法 |
US4868301A (en) * | 1987-06-09 | 1989-09-19 | Pfizer Inc. | Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains |
US4904782A (en) * | 1988-02-29 | 1990-02-27 | Pfizer Inc. | Process for the production of phthalazineacetic acid ester derivatives and a novel intermediate |
US4954629A (en) * | 1989-05-11 | 1990-09-04 | Pfizer Inc. | Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof |
WO1992003432A1 (en) * | 1990-08-28 | 1992-03-05 | Pfizer Inc. | 3-(5-trifluoromethylbenzothiazol-2-ylmethyl)-4-oxo-3h-phythalazin-1-ylacetic acid monohydrate |
US5391551A (en) * | 1993-05-10 | 1995-02-21 | Pfizer Inc. | Method of lowering blood lipid levels |
US6127367A (en) * | 1996-02-29 | 2000-10-03 | Pfizer, Inc. | Method of reducing tissue damage associated with non-cardiac ischemia |
-
1999
- 1999-08-06 EP EP99306252A patent/EP0982306A3/en not_active Withdrawn
- 1999-08-13 US US09/374,729 patent/US6159976A/en not_active Expired - Fee Related
- 1999-08-16 IL IL13141999A patent/IL131419A0/xx unknown
- 1999-08-17 IS IS5155A patent/IS5155A/is unknown
- 1999-08-17 AU AU44532/99A patent/AU4453299A/en not_active Abandoned
- 1999-08-18 TN TNTNSN99159A patent/TNSN99159A1/fr unknown
- 1999-08-18 MA MA25738A patent/MA26678A1/fr unknown
- 1999-08-19 UY UY25668A patent/UY25668A1/es not_active Application Discontinuation
- 1999-08-19 HU HU9902783A patent/HUP9902783A3/hu unknown
- 1999-08-19 OA OA9900185A patent/OA11150A/en unknown
- 1999-08-19 GT GT199900137A patent/GT199900137A/es unknown
- 1999-08-19 ZA ZA9905297A patent/ZA995297B/xx unknown
- 1999-08-19 CA CA002280590A patent/CA2280590A1/en not_active Abandoned
- 1999-08-19 EE EEP199900385A patent/EE9900385A/xx unknown
- 1999-08-19 YU YU39899A patent/YU39899A/sh unknown
- 1999-08-19 SG SG9904131A patent/SG83147A1/en unknown
- 1999-08-19 AP APAP/P/1999/001662A patent/AP9901662A0/en unknown
- 1999-08-20 EA EA199900675A patent/EA199900675A3/ru unknown
- 1999-08-20 PE PE1999000844A patent/PE20000993A1/es not_active Application Discontinuation
- 1999-08-20 BR BR9903873-0A patent/BR9903873A/pt not_active Application Discontinuation
- 1999-08-20 HR HR990259A patent/HRP990259A2/hr not_active Application Discontinuation
- 1999-08-20 KR KR1019990034527A patent/KR20000017411A/ko not_active Application Discontinuation
- 1999-08-20 TR TR1999/01996A patent/TR199901996A2/xx unknown
- 1999-08-20 NZ NZ337363A patent/NZ337363A/xx unknown
- 1999-08-20 ID IDP990796A patent/ID23307A/id unknown
- 1999-08-20 BG BG103674A patent/BG103674A/xx unknown
- 1999-08-20 PL PL99335016A patent/PL335016A1/xx not_active Application Discontinuation
- 1999-08-20 PA PA19998480601A patent/PA8480601A1/es unknown
- 1999-08-20 NO NO994027A patent/NO994027L/no not_active Application Discontinuation
- 1999-08-23 CN CN99118068A patent/CN1245804A/zh active Pending
- 1999-08-23 JP JP11235855A patent/JP2000072769A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
HUP9902783A2 (hu) | 2000-12-28 |
CA2280590A1 (en) | 2000-02-21 |
PA8480601A1 (es) | 2000-09-29 |
EP0982306A3 (en) | 2000-07-05 |
BR9903873A (pt) | 2000-09-19 |
AU4453299A (en) | 2000-03-09 |
EA199900675A2 (ru) | 2000-02-28 |
TNSN99159A1 (fr) | 2005-11-10 |
OA11150A (en) | 2003-04-16 |
EA199900675A3 (ru) | 2000-06-26 |
TR199901996A2 (xx) | 2000-03-21 |
AP9901662A0 (en) | 1999-09-30 |
KR20000017411A (ko) | 2000-03-25 |
YU39899A (sh) | 2002-12-10 |
PE20000993A1 (es) | 2000-10-04 |
IL131419A0 (en) | 2001-01-28 |
ZA995297B (en) | 2001-02-19 |
NO994027D0 (no) | 1999-08-20 |
NO994027L (no) | 2000-02-22 |
PL335016A1 (en) | 2000-02-28 |
EE9900385A (et) | 2000-04-17 |
MA26678A1 (fr) | 2004-12-20 |
US6159976A (en) | 2000-12-12 |
NZ337363A (en) | 2001-01-26 |
CN1245804A (zh) | 2000-03-01 |
GT199900137A (es) | 2001-02-09 |
ID23307A (id) | 2000-04-05 |
JP2000072769A (ja) | 2000-03-07 |
BG103674A (en) | 2000-03-31 |
IS5155A (is) | 2000-02-22 |
HUP9902783A3 (en) | 2001-01-29 |
SG83147A1 (en) | 2001-09-18 |
EP0982306A2 (en) | 2000-03-01 |
HU9902783D0 (en) | 1999-10-28 |
HRP990259A2 (en) | 2000-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4016264A (en) | Wart treatment with phosphonoacetic acid or derivatives thereof | |
McCutchan et al. | Xanthine oxidase-derived H2O2 contributes to reperfusion injury of ischemic skeletal muscle | |
UY25668A1 (es) | Polimorfo de monohidrato de zopolrestat | |
DE69636764D1 (de) | Zusammensetzungen zur behandlung von ischamischem gewebe | |
RU2006135487A (ru) | Соли присоединения кислоты 5-аминолевулиновой кислоты или ее производных | |
HN1996000085A (es) | Compuestos heterociclicos | |
DE60137635D1 (de) | Verwendung von allopurinol zur behandlung von bluthochdruck | |
US7125544B2 (en) | Kit for promoting the growth of human hair and its method of use | |
JP3012319B2 (ja) | 脳及び筋肉組織傷害による浮腫の治療剤 | |
Sotnı́ková | Investigation of the mechanisms underlying H2O2-evoked contraction in the isolated rat aorta | |
EE03003B1 (et) | Angiotensiin II retseptorite antagonistidena toimivad triasolopürimidiinide derivaadid, ravimvormid, nende valmistamise meetodid | |
Berne et al. | Acute coronary occlusion: Early changes that induce coronary dilatation and the development of collateral circulation∗ | |
ES2147629T3 (es) | Guanidinas de acido alquenilcarboxilico sustituidas con un grupo fluorofenilo como inhibidores del intercambio de na+/nh+, su procedimiento de preparacion y su uso como medicamento o agente diagnostico asi como el medicamento que las contiene. | |
BR0014895A (pt) | Formulação lìquida estável, processo para a preparação da mesma, uso da mesma, uso de polietileno glicol e sal de sódio ou potássio de um inibidor h+, k+-atpase, e, método para tratar doenças gastrointestinais | |
AR029229A1 (es) | Compuestos de piperazina sustituida, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de un medicamento | |
EP2010136B1 (en) | Methods for modulating formation and progression of cellulite | |
KR20080074890A (ko) | 아르테미시닌 및 그의 유도체를 이용한 양성 착색점(반점)의 처치 및 예방 | |
Onuigbo | Malignant melanoma in the Igbos of Nigeria | |
Ribari et al. | Cathepsin-B activity in otosclerosis | |
NO910033L (no) | Fremgangsmaate for fremstilling av terapeutisk aktive 2-hydroksy-3-fenoksypropylaminoforbindelser. | |
Isomatsu et al. | Left atrial myxoma associated with acute myocardial infarction | |
Tritthart et al. | The effects of the bradycardia-producing compound alinidine on action potentials and tension development in cardiac fibres | |
Glusa et al. | Dual effect of dihydroergotamine and dihydroergotoxin in isolated human femoral veins and arteries | |
RU2031651C1 (ru) | Способ удаления накожных бородавок | |
Ross | Some unsolved problems in the surgery of the sympathetic nervous system. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RDES | Application refused |
Effective date: 20110726 |